Trial Profile
An Open-label Randomized Multinational Phase 3 Trial of Nivolumab Versus Docetaxel in Previously Treated Subjects With Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 078: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 078)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 078
- Sponsors Bristol-Myers Squibb
- 26 Oct 2023 Status changed from discontinued to completed.
- 05 Sep 2023 Planned End Date changed from 15 Sep 2023 to 16 Nov 2023.
- 17 Aug 2023 Planned End Date changed from 1 Feb 2023 to 15 Sep 2023.